13 results for author: Sarah Motley


Phase One Sino-U.S. Trade Agreement and the Pharmaceutical Industry

On 16 January 2020, China and the United States signed the Economic and Trade Agreement between the Government of the People’s Republic of China and the Government of the United States of America (the Phase One Trade Agreement). The Phase One Trade Agreement includes a chapter on intellectual property aimed at resolving a wide range of key issues relating to intellectual property protection and enforcement, including, among other things, patents, pharmaceutical-related intellectual property and trade secrets. If properly performed and implemented through domestic legislation, the Phase One Trade Agreement would likely transform and modernise ...

Medicines – In Support of Follow-On Innovation

25 Sep 2018 In a recent article Professor Christopher Holman (University of Missouri - Kansas City School of Law) again comes out in support of patent protection for the embodiment of follow-on innovation in medicines (Christopher M. Holman, “Inside views: Why Follow-On Pharmaceutical Innovations Should Be Eligible For Patent Protection”, Intellectual Property Watch, 21 September 2018). Follow-on pharmaceutical innovation seeks to improve upon existing medicines by a range of alternatives such as offering a safer and more effective variation than the original product or creating a more patient- and treatment-friendly formulation. Despite its ...

Joint submission to the SPC on Post Filing data – February 2018

INTERPAT & IPO have submitted a white paper on the Determination of Experimental Post Filing Data. Click on the links below to read the submission: On the Determination of Post-Filing Experimental Data latest version Appendix File_On the Determination of Post-Filing Experimental Data.revised1